Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Jul 15:14:72.
doi: 10.1186/s12944-015-0071-9.

Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis

Yi-Yang Li  1 , Wen-Chao Zhang  2 , Jia-Ling Zhang  3 , Chang-Jun Zheng  4 , He Zhu  5 , Hui-Mei Yu  6 , Li-Mei Fan  7
Affiliations
Meta-Analysis

Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis

Yi-Yang Li et al. Lipids Health Dis. .

Abstract

Background: In this study, using a meta-analysis approach, we examined the correlation between serum levels of lysophosphastidic acid (LPA) and ovarian cancer (OC).

Methods: Relevant published studies were identified from multiple scientific literature databases by using a pre-determined electronic and manual search strategy. The search results were screened through a multi-step process to select high-quality case-control studies suitable for the present meta-analysis. Mean values and standardized mean differences (SMD) were calculated for plasma LPA levels. Two investigators independently extracted the data from the studies and performed data analysis using STATA software version 12.0 (Stata Corp, College Station, TX, USA).

Results: Nineteen case-control studies met our selection criteria and contained a total of 980 OC patients, 872 benign controls and 668 healthy controls. Our meta-analysis results revealed that the plasma levels of LPA in OC patients were significantly higher than benign controls (SMD = 2.36, 95% CI: 1.61-3.10, P < 0.001) and healthy controls (SMD = 2.32, 95% CI: 1.77-2.87, P < 0.001). Subgroup analysis by ethnicity showed that the plasma LPA levels in OC patients were significantly higher than the benign controls only in Asian populations (SMD = 2.52, 95% CI: 1.79-3.25, P < 0.001). However, a comparison between healthy controls and OC patients revealed that, in both Asians and Caucasians, the OC patients displayed significantly higher plasma LPA levels compared to healthy controls (all P < 0.05).

Conclusion: Our meta-analysis showed strong evidence that a significantly higher plasma LPA levels are present in OC patients, compared to benign controls and healthy controls, and plasma LPA levels may be used as a biomarker or target of OC.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart shows study selection procedure. Nineteen studies were included in this meta-analysis
Fig. 2
Fig. 2
The methodological quality of eligible studies using critical appraisal skill program criteria (+: Yes; −: No; ? : Unclear)
Fig. 3
Fig. 3
Forest plots for the relationship between plasma lysophosphatidic acid levels and ovarian cancer (a: Ovarian cancer patients VS. Benign controls; b: Ovarian cancer patients VS. Healthy controls)
Fig. 4
Fig. 4
Subgroup analysis for the relationships between plasma lysophosphatidic acid levels and ovarian cancer (a: Ethnicity: Ovarian cancer patients VS. Benign controls; b: Methods: Ovarian cancer patients VS. Benign controls; c: Ethnicity: Ovarian cancer patients VS. Healthy controls; d: Methods: Ovarian cancer patients VS. Healthy controls)
Fig. 5
Fig. 5
Funnel plot of publication biases on the relationship between plasma lysophosphatidic acid levels and ovarian cancer (a: Ovarian cancer patients VS. Benign controls; b: Ovarian cancer patients VS. Healthy controls)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama T, Kimura T, Yoshino K, et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012;21:1902–12. doi: 10.1158/1055-9965.EPI-12-0646. - DOI - PubMed
    1. Lowe KA, Chia VM, Taylor A, O’Malley C, Kelsh M, Mohamed M, et al. An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol. 2013;130:107–14. doi: 10.1016/j.ygyno.2013.03.026. - DOI - PubMed
    1. Sedlakova I, Vavrova J, Tosner J, Hanousek L. Lysophosphatidic acid (LPA)-a perspective marker in ovarian cancer. Tumour Biol. 2011;32:311–6. doi: 10.1007/s13277-010-0123-8. - DOI - PubMed
    1. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta. 2002;1582:257–64. doi: 10.1016/S1388-1981(02)00179-8. - DOI - PubMed

Publication types